Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

A patient who successfully used compounded GLP-1 medications to manage weight and health issues argues that the FDA's proposal to exclude these drugs from the 503B bulks list ignores real-world accessibility issues. They contend that because insurance often denies coverage for FDA-approved versions, compounded medications are a necessary and viable pathway to care for many patients.

An individual who uses compounded medication due to high costs and insurance denials expresses support for the action. They argue that expanding options for compounded drugs is necessary to improve quality of life and provide cost savings for patients facing a cost of living crisis.

A representative from a clinic (appearing as an individual) argues against the FDA's decision to move specific peptides to Category 2 of the Bulk Drug Evaluation list. They contend that these compounds are highly beneficial to patients with minimal safety risks and request that the FDA reconsider the move to prevent harm to their patients.

A representative from a clinic (appearing as an individual) argues against the FDA's decision to move specific peptides to Category 2 of the Bulk Drug Evaluation list. They contend that these compounds are highly beneficial to patients with minimal safety risks and request that the FDA reconsider the move to prevent harm to their patients.